Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.

Recognizing that cancer immunogenicity stems largely from variant peptides, 15 we predicted neo-antigens for each sample, which similarly showed a trend supporting the clinical benefit of SHR-1701.

also in 53,322 other papers

While the PR group exhibited higher tumor mutational burden (TMB), the difference did not reach statistical significance, likely due to the limited sample size (Fig. 4f ).

also in 111,027 other papers